Which Change in Therapy to Reduce CV Endpoints in T2DM?


You have reduced this patient's A1C to 6.9% by adding insulin. Suboptimal lipids and persistent hypertension now must be addressed. What change(s) would you make to her regimen?

A 68-year-old woman with a history of type 2 diabetes mellitus (T2DM), dyslipidemia, and hypertension presents to your clinic for routine follow-up. She is currently taking simvastatin 20 mg, hydrochlorothiazide 25 mg, metformin 1000 mg twice daily, and insulin, which you had added to her medical regimen at her last visit because of persistently difficult-to-control blood sugars. Repeat HbA1c at today’s visit is 6.9%.

Urinalysis shows no evidence of microalbuminuria and her most recent fasting lipid panel shows: total cholesterol, 150 mg/dL; HDL-C, 42 mg/dL; and LDL-C, 88 mg/dL. Vitals signs are: blood pressure, 148/69 mm Hg; and heart rate, 84 beats/min, in normal sinus rhythm. The remainder of her examination is unremarkable.

Which of the following medication changes is indicated and will reduce her risk of having a cardiovascular event in the future?

A. Add saxagliptin 5 mg daily
B. Switch simvastatin 20 mg daily to atorvastatin 40 mg daily
C. Add an ACE inhibitor
C. Both B and C
D. All of the above
Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.